medigraphic.com
ISSN 1561-3070 (Electronic)

2020, Number 1

<< Back Next >>

Rev Cub Oftal 2020; 33 (1)

Recurrent pterygium and its therapeutic alternatives

Hernández FY, León RY, Pérez PZ, Jareño OM, Moreno RM, Benítez MMC

Language: Spanish
References: 24
Page: 1-12
PDF size: 289.87 Kb.


ABSTRACT

Pterygium is a fibrovascular growth of triangular shape that extends from the conjunctiva to the cornea. It has been classified as a noninvolutionary degeneration or benign corneal epithelial tumor which affects 10.2% of the population. The treatment most commonly indicated is surgery, which has a recurrence rate of 10.7%, irrespective of the surgical technique used. Recurrence takes the form of neovascularization and scar tissue within two months after surgery. This has fostered research into new treatments to reduce this complication. The objective of the present bibliographic review was precisely to search for therapeutic alternatives for recurrent pterygium. An automated search was conducted about the topic on the platform Infomed. Data were summarized to write the final report. We concluded that there are several adjuvant treatments to reduce recurrence, and it is necessary to carry out studies determining the time and frequency of their application to obtain more effective results.


REFERENCES

  1. Vaugham D. Enfermedades de la conjuntiva. Oftalmología General. México DF: El Manual Moderno; 2004:133.

  2. Rezvan F, Khabazkhoob M, Hooshmand E, Yekta A, Saatchi M, Hashemi H. Prevalence and risk factors of pterygium: a systematic review and meta-analysis. Surv Ophthalmol. 2018 [acceso: 20/07/2019];63(5):719-35. Displonible en: https://www.sciencedirect.com/science/article/abs/pii/

  3. Campagna G, Adams M, Wang L, Khandelwal S, Al-Mohtaseb Z. Comparison of pterygium recurrence rates among different races and ethnicities after primary pterygium excision by surgeons in training. Cornea [Internet]. 2018 [acceso: 02/05/2019];37(2):199-204. Disponible en: https://journals.lww.com/corneajrnl/Fulltext/2018/02000/Comparison_of_Pterygium_Recurren ce_Rates_Among

  4. Cárdenas-Cantú E, Zavala J, Valenzuela J, Valdez-García JE. Molecular basis of pterygium development. Semin Ophthalmol. 2016;31(6):567-83.

  5. American Academy of Ophthalmology. External Disease and Cornea. Basic and Clinical Science Course 2014-2015. San Francisco: American Academy of Ophthalmology; 2014.

  6. Kaufman SC, Jacobs DS, Lee WB, Deng SX, Rosenblatt MI, Shtein RM. Options and adjuvants in surgery for pterygium. Ophthalmology. 2013;120(1):201-8.

  7. Bilge AD. Comparison of conjunctival autograft and conjunctival transposition flap techniques in primary pterygium surgery. Saudi J Ophthalmol. 2018;32(2):110-3.

  8. Kumar S, Singh R. Pterygium excision and conjunctival autograft: a comparative study of techniques. Oman J Ophthalmol. 2018;11(2):124-8.

  9. Nuzzi R, Tridico F. How to minimize pterygium recurrence rates: clinical perspectives. Clin Ophthalmol. 2018;12(2):347-62.

  10. Mohammed I. Treatment of pterygium. Ann Afr Med. 2011;10:197-203.

  11. Fuest M, Liu Y, Hin-Fai Yam G, Coroneo MT, Mehta JS. Femtosecond Laser Assisted Pterygium Surgery. Cornea [internet]. 2017 [acceso: 17/08/2019];36(17):889-92. Disponible en: https://www.smo.org.mx/archivos/smonline/cornea/articulos/889-892.pdf

  12. Carraca Fonseca E, Melani Rocha E, Viani Arruda G. Comparison among adjuvant treatments for primary pterygium: a network meta-analysis. London: Brit J Opthalmol. 2018;102(6):748-56.

  13. Hacıog˘lu D, Erdo¨l H. Developments and current approaches in the treatment of pterygium. Int Ophthalmol. 2017;37:1073-81.

  14. Hovanesian JA, Starr CE, Vroman DT, Mah FS, Gomes JAP, Farid M, et al. Surgical techniques and adjuvants for the management of primary and recurrent pterygia. J Cataract Refract Surg. 2017;43:405-19.

  15. Garza Cantu D, Barba Navarrete DM, García Guerrero Jair, González Treviño JL. Uso de bevacizumab para reducir la recurrencia de pterigión posterior a tratamiento quirúrgico. Rev Mex Oftalmol. 2013;87(2):113-8.

  16. Shenasi A, Mousavi F, Shoa-Ahari S, Rahimi-Ardabili B, Fouladi RF. Subconjunctival bevacizumab immediately after excision of primary pterygium: the first clinical trial. Cornea. 2011;30(11):1219-22.

  17. Sun Y, Zhang B, Jia X, Ling S, Deng J. Efficacy and safety of bevacizumab in the treatment of pterygium: an updated meta-analysis of randomized controlled trials. J Ophthalmol. 2018;173-9.

  18. Guma S, Hee Kimab Y, Chang Jung J, Gyu Kima I, Seok Lee J, Won Lee . Cyclosporine A inhibits TGF-β2-induced myofibroblasts of primary cultured human pterygium fibroblasts. Biom Bioph Res Communicat. 2017;428(4):1148-53.

  19. Zhang Q, Bao N, Liang K, Tao L. Adjuvant use of cyclosporine a in the treatment of primary pterygium: a systematic review and meta-analysis. Cornea. 2018;37(8):1000-7.

  20. Fernandes de Sousa Meneghim RL, Horikawa Satto L, Leiko Natsuaki K, Carvalho de Oliveira A, Roberto Padovani C, Hata Viveiros MM. Ciclosporina A 0,05 % antes e após a cirurgia do pterígio para a prevenção da recorrência. Arq Bras Oftalmol. 2019;82(5):372-6.

  21. Hossien Davari M, Ghitasi H, Davari E.Treatment of recurrent pterygium with topical administration of interferon alpha-2b: A case report. J Surg Trauma. 2015;3:30-2.

  22. Carlock BH, Bienstock CA, Rogosnitzky M. Pterygium: Nonsurgical treatment using topical dipyridamole - a case report. Case Rep Ophthalmol [Internet]. 2014 [acceso: 17/05/2019];5(1):98-103. Disponible en: http://www.karger.com?doi=10.1159/000362113

  23. Barraquer RI, Charvenrook VK. Management of Recurrent Pterygium. En: Kayra Mejia/Eduardo Chandeck. New Trends in Ophthalmology. Panamá. Highlights; 2013;51-60.

  24. Kampitak K, Leelawongtawun W, Leeamornsiri S, Suphachearaphan W. Role of artificial tears in reducing the recurrence ofpterygium after surgery: a prospective randomized controlled trial. Acta Ophthalmol. 2017:95;227-9.




2020     |     www.medigraphic.com